Biopharmaceutical company Avacta Therapeutics (AIM: AVCT) reported on Wednesday that it presented new data comparing its pre|CISION tumour-activated delivery platform with approved antibody-drug conjugates (ADCs), alongside updated results from its AVA6207 dual payload programme, at its Science Day 2026 event.

In the AVA6103 programme, comparative analyses versus Enhertu and Datroway showed faster tumour penetration and higher peak concentrations of released exatecan, with a Tmax of minutes compared to over 24 hours for comparator ADCs. The tumour selectivity index was at least three times higher for AVA6103, indicating greater tumour exposure relative to bloodstream levels. The company plans to present these findings at an academic conference and in a peer-reviewed publication.

Updated in vivo data from the AVA6207 programme demonstrated deep and durable complete responses in tumour models, including cases where conventional cytotoxic therapies and comparator ADCs showed tumour regrowth. Results in both FAP-high and FAP-low/HER2-positive models suggest improved efficacy of the dual payload approach.

Avacta's pre|CISION platform is designed to release potent therapies selectively within the tumour microenvironment using fibroblast activation protein targeting, with the aim of improving efficacy while reducing systemic toxicity.